Destiny Pharma plc
LSE: DEST.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher John Tovey BSc
- Employees
- 15
- Headquarters
- Brighton, United Kingdom
- IPO year
- 2017
- Market cap
- £2.9M
- Website
- https://www.destinypharma.com
Loading DEST…
Loading profile data…Frequently asked questions about DEST
What does Destiny Pharma plc (DEST.L) do?
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, w...
Where does DEST.L trade?
Destiny Pharma plc (DEST.L) trades on the London Stock Exchange.
What sector is DEST.L in?
Destiny Pharma plc (DEST.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Destiny Pharma plc?
Christopher John Tovey BSc is the chief executive officer of Destiny Pharma plc (DEST.L).
Where is Destiny Pharma plc headquartered?
Destiny Pharma plc is headquartered in United Kingdom.
Does DEST.L pay a dividend?
Destiny Pharma plc (DEST.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DEST.L go public?
Destiny Pharma plc (DEST.L) completed its initial public offering in 2017.